Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 13, 2007. The report details a specific corporate action regarding a share repurchase authorized by shareholders at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes related to a share buyback.
- Shares Purchased: 750,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,307.42 pence per share.
- Treasury Holdings: 313,989,158 shares (representing 5.50% of total voting rights).
- Shares in Issue: 5,706,694,635 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 750,000 shares on June 13, 2007. These shares are intended to be held in Treasury. Consequently, the total number of shares in issue (excluding Treasury) remains 5,706,694,635, which serves as the denominator for shareholder notification calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,706,694,635) for compliance with disclosure thresholds.
- Confirm the updated Treasury share count (313,989,158) and its impact on total voting rights (5.50%).
- Review the authorization details from the Annual General Meeting held on May 23, 2007.